PARP inhibitor olaparib increases the oncolytic activity of dl922‐947 in in vitro and in vivo model of anaplastic thyroid carcinoma

PARP inhibitors are mostly effective as anticancer drugs in association with DNA damaging agents. We have previously shown that the oncolytic adenovirus dl922‐947 induces extensive DNA damage, therefore we hypothesized a synergistic antitumoral effect of the PARP inhibitor olaparib in association wi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Main Authors: Passaro, Carmela, Volpe, Massimiliano, Botta, Ginevra, Scamardella, Eloise, Perruolo, Giuseppe, Gillespie, David, Libertini, Silvana, Portella, Giuseppe
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2014
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528680/
https://ncbi.nlm.nih.gov/pubmed/25139258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2014.07.022
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados